Management of Bcr-Abl-positive leukemias with dasatinib.
about
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
P2860
Management of Bcr-Abl-positive leukemias with dasatinib.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Management of Bcr-Abl-positive leukemias with dasatinib.
@en
Management of Bcr-Abl-positive leukemias with dasatinib.
@nl
type
label
Management of Bcr-Abl-positive leukemias with dasatinib.
@en
Management of Bcr-Abl-positive leukemias with dasatinib.
@nl
prefLabel
Management of Bcr-Abl-positive leukemias with dasatinib.
@en
Management of Bcr-Abl-positive leukemias with dasatinib.
@nl
P2860
P1476
Management of Bcr-Abl-positive leukemias with dasatinib.
@en
P2860
P304
P356
10.1586/14737140.7.11.1529
P577
2007-11-01T00:00:00Z